We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & ...

FMC is in poor financial health. We calculate a net debt/adjusted EBITDA ratio of 4.3 times as of March 31. We expect FMC's leverage ratios will remain elevated over the next several years. However, ...

"We built Ketryx so quality and product development teams can harness the power of AI, a power so impactful it is the equivalent of tens of thousands of round-the-clock workers perpetually sifting ...